<DOC>
	<DOCNO>NCT00524810</DOCNO>
	<brief_summary>Evaluation safety efficacy treatment associate Pegylated Liposomal Doxorubicin + Docetaxel patient metastatic breast cancer</brief_summary>
	<brief_title>Liposomal Doxorubicin Docetaxel Metastatic Breast Cancer</brief_title>
	<detailed_description>Evaluation safety efficacy treatment associate Pegylated Liposomal Doxorubicin + Docetaxel patient metastatic breast cancer . Patients receive pyridoxin prevent cutaneo-mucinous toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>first metastatic chemo line presence measurable bone lesion least one lesion outside radiate area previously receive hormonotherapy , chemotherapy adjuvant phase , radiotherapy old 4 week local tumoral progression symptomatic cerebral metastasis neuropathy &gt; NCICTC 2 previous cancer within 10 year _ previous cancer within 10 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>